Silexion Therapeutics公布积极临床前数据，显示Sil204经系统给药后可到达胰腺癌主要转移部位并发挥活性_老虎社区_美港股上老虎

Silexion Therapeutics公布积极临床前数据，显示Sil204经系统给药后可到达胰腺癌主要转移部位并发挥活性

美股速递09-11 19:02

Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据，证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1118879000?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-11 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118879000","market":"us","top_or_hot":-1,"title":"Silexion Therapeutics公布积极临床前数据，显示Sil204经系统给药后可到达胰腺癌主要转移部位并发挥活性","media":"美股速递","content":"<p>Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据，证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silexion Therapeutics公布积极临床前数据，显示Sil204经系统给药后可到达胰腺癌主要转移部位并发挥活性</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilexion Therapeutics公布积极临床前数据，显示Sil204经系统给药后可到达胰腺癌主要转移部位并发挥活性\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2025-09-11 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据，证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1118879000","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118879000","pubTimestamp":1757588575,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据，证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","SLXN":"Silexion Therapeutics Corp"},"translate_title":"Silexion Therapeutics announces positive preclinical data showing that Sil204 can reach major metastatic sites of pancreatic cancer and become active after systemic administration","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLXN":1},"content_text":"Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据，证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}